drugset
drugset / Trial / NCT02634827

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

NCT02634827 ↗

Phase 2 Terminated 1 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well midostaurin and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia and FLT3 mutations. Midostaurin and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2015-12-30
Primary completion
2017-03-18
Completion
2018-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule — Intravenous
Subject Midostaurin Small molecule — Oral

Indications

acute myeloid leukemia, FLT3 internal tandem duplication acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation